In two replicate Phase 3 studies, upadacitinib (RINVOQ®) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial… Read More
Based on the DESTINY-Breast06 phase III trial results demonstrating statistically significant and clinically meaningful progression-free survival benefit in patients treated with Enhertu vs. conventional chemotherapy Mississauga, ON – Health Canada… Read More
New ‘baited-SELEX’ technology merges small-molecule drug design with chemical biology to potentially improve treatment accuracy and reduce side effects. A collaborative team of researchers from the Department of Chemistry at… Read More
Four research teams across Canada have received a total of $14.5 million though the 2025 Terry Fox New Frontiers Program Project Grants (PPGs), a longstanding funding program supporting projects exploring… Read More
The U.S. FDA has granted Breakthrough Device Designation to SPINEstat® (14-3-3eta Autoantibody Multiplex Immunoassay Test), recognizing its potential to address a significant unmet need in the diagnosis of patients with… Read More
